Current (US) patent system promotes long-term instead of preventative treatments (Cancer)

“Our empirical work investigates this distortion empirically in the context of the pharmaceutical industry, where drugs treating patients with short life expectancies can move through clinical trials more quickly – and thus receive longer effective patent terms – than drugs treating patients with long life expectancies. Using a newly constructed data set on cancer clinical trial investments, we provide several sources of evidence consistent with fixed patent terms distorting cancer R&D away from drugs targeting early-stage cancer patients or cancer prevention.”
National Bureau of Economic Research, September 2013

Covered in:
Slate, Aug 2013


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s